3SBio Outlines Plans For $540m IPO Spoils
This article was originally published in PharmAsia News
Executive Summary
China biotech firm 3SBio, which delisted from Nasdaq in 2013, has raised HKD$4.17bn ($540 million) through an initial public offering on the Hong Kong stock exchange, which it will use mainly to expand its product portfolio and pipeline.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.